**Supplementary Information**



**Suppl. Figure 1. Gating strategy to identify monocytes and DC subpopulations in PBMCs.** PBMCs were isolated from whole blood and stained using different antibodies. Gating strategies of slanDCs, monocytes, mDCs, pDCs and are shown.



**Suppl. Figure 2. Production of cytokines by slanDCs.** PBMCs were isolated from whole blood of untreated HIV-1 infected or healthy donors and incubated for 16 h in the presence of LPS. A-C) slanDCs were stained for intracellular IL-10 (A, n=6), IL-12 (B, n=6) and TNF-a (C, n=6) expression and the percentage of cytokine expressing cells were shown. \*\**p* < 0.01 and \*\*\**p* < 0.001, Unpaired *t*-tests.



**Suppl. Figure 3. IL-1β production of monocytes.** PBMCs were isolated from whole blood of untreated HIV-1 infected or healthy donors and incubated for 16 h in the presence of LPS. Monocytes were stained for intracellular IL-1β expression and the percentage of IL-1β+ cells in classical CD14+ (blue bar), CD14+CD16+ (green bar) and CD14lowCD16+( red bar) monocytes is shown (n=6/group). \**p* < 0.05 and \*\**p* < 0.01 , One-way ANOVA followed by Bonferroni posttests.

**Suppl. Table 1. Clinical data of HIV-1 infected patient samples used for the study**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patient Number** | **Age** | **Sex** | **ART Therapy** | **CD4+ T cells/L** | **VL log10 RNA copies/mL** |
| **1** | 32 | F | No | 203 | 3.36 |
| **2** | 46 | M | No | 468 | 3.22 |
| **3** | 40 | F | No | 482 | 3.33 |
| **4** | 48 | M | No | 497 | 1.30 |
| **5** | 36 | F | No | 1085 | 2.87 |
| **6** | 41 | M | No | 300 | 4.57 |
| **7** | 50 | M | No | 383 | 4.37 |
| **8** | 46 | M | No | 441 | 3.98 |
| **9** | 40 | F | No | 760 | 1.30 |
| **10** | 37 | F | No | 723 | 2.32 |
| **11** | 45 | M | No | 962 | 3.96 |
| **12** | 44 | M | No | 412 | 3.14 |
| **13** | 27 | M | No | 480 | 5.17 |
| **14** | 46 | M | No | 600 | 3.81 |
| **15** | 39 | M | No | 6 | 6.19 |
| **16** | 48 | M | No | 805 | 2.78 |
| **17** | 46 | M | No | 56 | 4.48 |
| **18** | 52 | M | No | 80 | 4.79 |
| **19** | 40 | F | Yes | 221 | 1.30 |
| **20** | 63 | M | Yes | 355 | 2.45 |
| **21** | 41 | F | Yes | 534 | 1.30 |
| **22** | 32 | F | Yes | 480 | 1.34 |
| **23** | 70 | M | Yes | 570 | 1.32 |
| **24** | 42 | F | Yes | 47 | 1.30 |
| **25** | 26 | F | Yes | 299 | 1.3 |
| **26** | 47 | M | Yes | 508 | 1.5 |
| **27** | 52 | M | Yes | 1023 | 1.3 |
| **28** | 39 | M | Yes | 834 | 1.3 |
| **29** | 51 | M | Yes | 1026 | 2.9 |
| **30** | 71 | M | Yes | 308 | 1.3 |
| **31** | 70 | M | Yes | 603 | 1.3 |

ART, antiretroviral therapy; F, female; M, male; VL, viral load